Immunization of Guinea Pigs with Novel Hepatitis B Antigen as Nanoparticle Aggregate Powders Administered by the Pulmonary Route

Novel nanoparticle-aggregate formulations containing recombinant hepatitis B surface antigen (rHBsAg) were administered to the lungs of guinea pigs and antibodies generated to this antigen evaluated. Preparations of dry powders of: (a) rHBsAg encapsulated within poly(lactic-co-glycolic acid) (PLGA)/polyethylene glycol (PEG) nanoparticles (antigen nanoparticles, AgNSD), (b) rHBsAg in a physical mixture with blank PLGA/PEG nanoparticles (antigen nanoparticle admixture (AgNASD), and (c) rHBsAg encapsulated in PLGA/PEG nanoparticles plus free rHBsAg (antigen nanoparticles and free antigen), were generated by spray drying with leucine. Control groups consisted of alum with adsorbed rHBsAg (AlumAg); reconstituted suspensions of spray-dried rHBsAg-loaded PLGA/PEG nanoparticles with leucine; and rHBsAg-loaded PLGA/PEG nanoparticles (AgN). Control preparations were administered by intramuscular injection; AgN was also spray instilled into the lungs. The IgG titers were measured in the serum for 24 weeks after the initial immunization; IgA titers were measured in the bronchio-alveolar lavage fluid. While the highest titer of serum IgG antibody was observed in guinea pigs immunized with AlumAg administered by the IM route, animals immunized with powder formulations via the pulmonary route exhibited high IgA titers. In addition, guinea pigs immunized with AgNASD via the pulmonary route exhibited IgG titers above 1,000 mIU/ml in the serum (IgG titers above 10 mIU/ml is considered protective). Thus, the disadvantages observed with the existing hepatitis B vaccine administered by the parenteral route may be overcome by administering them as novel dry powders to the lungs. In addition, these powders have the advantage of eliciting a high mucosal immune response in the lungs without traditional adjuvants.

[1]  F. Deinhardt,et al.  Persistence of specific antibodies after hepatitis B vaccination. , 1988, Journal of hepatology.

[2]  R. Fontana.  Management of Patients with Decompensated HBV Cirrhosis , 2003, Seminars in liver disease.

[3]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .

[4]  B. Pulliam,et al.  Nanoparticles for drug delivery to the lungs. , 2007, Trends in biotechnology.

[5]  B. Pulliam,et al.  Design of nanoparticle-based dry powder pulmonary vaccines , 2007, Expert opinion on drug delivery.

[6]  Hitoshi Sato,et al.  Induction of humoral and cell-mediated immunity to hepatitis B surface antigen by a novel adjuvant activity of Oka varicella vaccine. , 2003, The Journal of general virology.

[7]  Y. Barenholz,et al.  Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. , 2002, Vaccine.

[8]  Manmohan J. Singh,et al.  Microparticles as vaccine adjuvants and delivery systems , 2003, Expert review of vaccines.

[9]  P A Singer,et al.  Grand Challenges in Global Health , 2003, Science.

[10]  R. Gupta,et al.  Adjuvants for human vaccines--current status, problems and future prospects. , 1995, Vaccine.

[11]  J. Holmgren,et al.  Recent advances in mucosal vaccines and adjuvants. , 2002, Current opinion in immunology.

[12]  T. Wright,et al.  The epidemiology and prevention of hepatocellular carcinoma. , 2001, Seminars in oncology.

[13]  M. Isaka,et al.  Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. , 2001, Vaccine.

[14]  A. Krieg,et al.  CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. , 1998, Journal of immunology.

[15]  P. Holt,et al.  Pulmonary dendritic cells in local immunity to inert and pathogenic antigens in the respiratory tract. , 2005, Proceedings of the American Thoracic Society.

[16]  D. Metze,et al.  Persistent nodules at injection sites (aluminium granuloma)—clinicopathological study of 14 cases with a diverse range of histological reaction patterns , 2006, Histopathology.

[17]  R. Purcell,et al.  Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates , 1999, Molecular medicine.

[18]  M. I. Jirón,et al.  Hepatitis B vaccine , 2016, Reactions Weekly.

[19]  S. Vyas,et al.  Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. , 2006, Vaccine.

[20]  P. Holt,et al.  Anatomical Location Determines the Distribution and Function of Dendritic Cells and Other APCs in the Respiratory Tract1 , 2005, The Journal of Immunology.

[21]  B. Bloom,et al.  Immunization by a bacterial aerosol , 2008, Proceedings of the National Academy of Sciences.

[22]  H. Hoogsteden,et al.  Lung dendritic cells and host immunity to infection. , 2001, The European respiratory journal.

[23]  H. Alpár,et al.  Adjuvant synergy: The effects of nasal coadministration of adjuvants , 2004, Immunology and cell biology.

[24]  C. Howard,et al.  48‐mer synthetic peptide analogue of the hepatitis B virus “a” determinant induces an anti‐HBs antibody response after a single injection , 2000, Journal of medical virology.

[25]  L. Finelli,et al.  Hepatitis B and Hepatitis D Viruses , 2008 .

[26]  Y. Wen,et al.  Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. , 1998, Viral immunology.

[27]  S. Kaufmann.  Novel vaccination strategies. , 2004 .

[28]  A. Hickey,et al.  Pulmonary vaccine delivery , 2007, Expert review of vaccines.

[29]  Man-Fung Yuen,et al.  Viral hepatitis B , 2003, The Lancet.

[30]  T. Volz,et al.  Animal models for the study of HBV replication and its variants. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[31]  F. Cutts,et al.  Alternative routes of measles immunization: a review. , 1997, Biologicals : journal of the International Association of Biological Standardization.

[32]  R. Feigin,et al.  Textbook of Pediatric Infectious Diseases , 1986 .

[33]  Kambiz Gilani,et al.  The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with L-leucine. , 2004, International journal of pharmaceutics.

[34]  J. Zuckerman,et al.  Current topics in hepatitis B. , 2000, The Journal of infection.

[35]  J. Birchall,et al.  Enhanced Dispersibility and Deposition of Spray-dried Powders for Pulmonary Gene Therapy , 2003, Journal of drug targeting.

[36]  J. Tomašić,et al.  Comparison of immunogenicity of recombinant and plasma derived hepatitis B antigen in guinea-pigs. , 1990, Vaccine.

[37]  W. Hennink,et al.  Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs. , 2007, Vaccine.

[38]  L. Simonsen,et al.  Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. , 1999, Bulletin of the World Health Organization.